Home  »  Advanced non-Hodgkin lymphoma

Advanced non-Hodgkin lymphoma

Access to genomic sequencing may lead to more accurate diagnosis at an earlier stage, as well as a greater capacity to tailor treatment for each lymphoma patient.

Lymphoma is the most common form of blood cancer in Australia, and the sixth most common cancer overall. Around 90% of lymphoma is non-Hodgkin.

Even with the best of available treatment, up to 50% of patients with high-risk advanced non-Hodgkin lymphoma will die of their disease. Access to genomic sequencing may lead to more accurate diagnosis at an earlier stage, as well as a greater capacity to tailor treatment for each patient. Genomic sequencing can also provide evidence to support a patient’s pre-selection for clinical trials or compassionate drug access initiatives.

Click here for more information Melbourne Genomics' lymphoma project.